Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20209452 | 0.95 | MAPT (0.42) | MAPTSLC6A4SLC6A3NOS2NOS3 | |
| SCHEMBL20833461 | 0.95 | MAPT (0.42) | MAPTSLC6A4SLC6A3NOS2NOS3 | |
| SCHEMBL20208763 | 0.95 | MAPT (0.42) | MAPTSLC6A4SLC6A3NOS2NOS3 | |
| SCHEMBL20833049 | 0.93 | MAPT (0.41) | MAPTSLC6A4SLC6A3NOS2NOS3 | |
| SCHEMBL6288977 | 0.93 | MAPT (0.41) | MAPTSLC6A4SLC6A3NOS2NOS3 | |
| SCHEMBL4475990 | 0.93 | — | — | |
| SCHEMBL4475988 | 0.93 | — | — | |
| SCHEMBL20833217 | 0.88 | MAPT (0.46) | MAPTSLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL20832968 | 0.88 | MAPT (0.46) | MAPTSLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL20833230 | 0.88 | MAPT (0.46) | MAPTSLC6A4SLC6A3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-23 | — | — | US | disclosed |
| WO-2019055951-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | MAPT 4748/4885SLC6A4 1561/4885SLC6A3 3086/4885 |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | MAPT 1403/4885SLC6A4 2946/4885SLC6A3 3986/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | MAPT 1403/4885SLC6A4 2946/4885SLC6A3 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.